Test Reversion After Latent TB Treatment
After completing latent TB treatment, approximately 46% of patients with initially positive IGRA tests will revert to negative, while only about 14% of those with positive TST will revert to negative 1.
Key Evidence on Test Reversion
The most relevant data comes from a prospective study of patients receiving TNF-α inhibitor therapy who were treated with isoniazid for latent TB 1. This study directly measured test reversion rates:
- IGRA reversion rate: 46.2% (6 out of 13 patients with baseline positive IGRA)
- TST reversion rate: 13.6% (3 out of 22 patients with baseline positive TST)
These findings were observed after a median follow-up of approximately 35 weeks during ongoing immunosuppressive therapy.
Clinical Implications
The likelihood of test negativity differs substantially between the two testing modalities:
- IGRAs are more likely to revert after successful treatment, with nearly half of treated patients showing negative results on retesting
- TST remains positive in the vast majority (>85%) of treated patients, likely due to persistent immunologic memory to tuberculin antigens
Important Caveats
The clinical significance of persistent test positivity after treatment completion remains uncertain 1. Critically, patients whose IGRA remained positive after isoniazid treatment did not develop active TB during follow-up, questioning whether persistent positivity indicates treatment failure or simply reflects immunologic memory without ongoing infection risk.
Practical Considerations
Routine retesting after latent TB treatment completion is not recommended by current guidelines 2. The WHO guidelines for low TB burden countries do not advocate for test-of-cure approaches, as:
- Test reversion does not reliably predict treatment success
- Persistent positivity does not necessarily indicate treatment failure or need for retreatment
- No cases of TB reactivation occurred regardless of post-treatment test results 1
If retesting is performed for specific clinical reasons, IGRA is more likely than TST to demonstrate negativity, but this should not be interpreted as the sole marker of treatment efficacy.